OnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on Thursday

Posted by ABMN Staff on Mar 25th, 2025

OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) is expected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect OnKure Therapeutics to post earnings of ($1.08) per share for the quarter.

OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) last released its quarterly earnings results on Monday, March 10th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51). On average, analysts expect OnKure Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

OnKure Therapeutics Price Performance

OKUR stock opened at $4.96 on Tuesday. OnKure Therapeutics has a fifty-two week low of $4.45 and a fifty-two week high of $20.00. The stock has a market cap of $66.64 million, a P/E ratio of -0.41 and a beta of 0.28. The stock’s 50 day moving average price is $5.39.

Analyst Ratings Changes

OKUR has been the subject of several recent research reports. Leerink Partners began coverage on OnKure Therapeutics in a research report on Thursday, December 5th. They set an “outperform” rating and a $33.00 price objective for the company. Oppenheimer lowered their price target on shares of OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research report on Tuesday, March 11th. HC Wainwright decreased their target price on shares of OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th. Finally, Leerink Partnrs raised OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $32.33.

Read Our Latest Report on OKUR

About OnKure Therapeutics

(Get Free Report)

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.